The FDA’s Antibiotics Advisory Panel voted 16 to 1 in favor of paxlovid, indicating that the drug safe and effective To treat COVID-19 in high-risk adults.
Paxlovid has been granted Emergency Use Authorization in December 2021. millions of americans For the treatment of coronavirus infections.
This approval came shortly after the FDA determined that the drug was effective and was not related to what is called “paxlovid rebound,” in which symptoms recur shortly after completing a course of treatment.
Treatments like paxlovid, along with Merck and Ridgeback’s fellow COVID-19 antiviral drug molnupiravir, have been approved by the White House Test-to-Treat Initiative This was intended to give people quick and easy access to medicine after testing positive for coronavirus infection.
However, this drug has some drawbacks. interactions with other drugs Prescribing is often not possible when it means stopping another prescription the patient is taking.
And while full approval would add another feather to Pfizer’s cap, the company itself isn’t expecting much profit from the drug, at least not this year. We anticipate a 58% decrease in revenue from Paxlovid in 2023 due to the termination of the contract.
